Workflow
Bionano Genomics(BNGO)
icon
Search documents
Bionano Genomics(BNGO) - 2022 Q1 - Earnings Call Transcript
2022-05-06 00:16
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano Genomics First Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Investor Rel ...
Bionano Genomics(BNGO) - 2022 Q1 - Quarterly Report
2022-05-04 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | |--- ...
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin at 2nd Annual Maxim Group Virtual Growth Conference (Transcript)
2022-03-30 23:25
Bionano Genomics, Inc. (NASDAQ:BNGO) 2nd Annual Maxim Group Virtual Growth Conference March 30, 2022 3:30 PM ET Company Participants Erik Holmlin - Chief Executive Officer Conference Call Participants Jason McCarthy - Maxim Group Michael Okunewitch — Maxim Group Jason McCarthy Welcome back everyone. Today we are bringing you Erik Holmlin, the CEO of Bionano Genomics. Bionano’s developing Optical Genome Mapping or OGM which is a genomic interrogation technique that provides long range structural information ...
Bionano Genomics(BNGO) - 2021 Q4 - Earnings Call Transcript
2022-03-02 00:25
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Amy Conrad – Investor Relations Erik Holmlin – Chief Executive Officer Chris Stewart – Chief Financial Officer Conference Call Participants Sung Ji Nam – BTIG Destiny Buch – Ladenburg Thalmann Kevin DeGeeter – Oppenheimer Michael Okunewitch – Maxim Group Operator Good day, and welcome to the Bionano Genomics Fourth Quarter and Full Year 2021 Earnings Conference Call. Today’s conference is bein ...
Bionano Genomics(BNGO) - 2021 Q4 - Annual Report
2022-02-28 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM Commission File Number 001-38613 Bionano Genomics, Inc. | --- | --- | |-------------------------------------------------------------------------- ...
Bionano Genomics(BNGO) - 2021 Q3 - Earnings Call Transcript
2021-11-05 20:17
Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Rich Shippy - CBO Conference Call Participants Destiny Buch - Ladenburg Thalmann Kevin DeGeeter - Oppenheimer Operator Good day, and welcome to the Bionano Genomics' Third Quarter 2021 Earnings Conference Call. Today's conference is being recorded. At this time, I'd like to turn th ...
Bionano Genomics(BNGO) - 2021 Q3 - Quarterly Report
2021-11-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file numb ...
Bionano Genomics(BNGO) - 2021 Q2 - Earnings Call Transcript
2021-08-05 02:12
Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Amy Conrad – Investor Relations Erik Holmlin – Chief Executive Officer Alka Chaubey – Chief Medical Officer Chris Stewart – Chief Financial Officer Conference Call Participants Sung Ji Nam – BTIG Jeffrey Cohen – Ladenburg Thalmann Jason McCarthy – Maxim Group Susan Chor – Oppenheimer Operator Good day, and welcome to the Bionano Genomics Second Quarter 2021 Earnings Conference Call. Today’s c ...
Bionano Genomics(BNGO) - 2021 Q2 - Quarterly Report
2021-08-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | --- | ...
Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin Presents at Oppenheimer MedTech, Tools & Diagnostics Summit Conference (Transcript)
2021-05-26 15:29
Bionano Genomics, Inc. (NASDAQ:BNGO) Oppenheimer MedTech, Tools & Diagnostics Summit Conference Call May 26, 2021 8:00 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Erik Holmlin Well, I am really excited to be here today and talk to you about Bionano Genomics. I'm Erik Holmlin, the President and CEO. I also want to thank everybody at Oppenheimer for the opportunity to participate in this summit. Of course, I'll be talking through some forward-lo ...